Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Organovo (NASDAQ:ONVO) in a research note issued to investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Organovo stock opened at $2.12 on Friday. Organovo has a 1-year low of $1.96 and a 1-year high of $21.96. The company’s 50-day moving average is $4.70 and its 200 day moving average is $4.95. The firm has a market capitalization of $3.61 million, a P/E ratio of -2.49 and a beta of 1.13.

Organovo (NASDAQ:ONVO) last issued its earnings results on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.24. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.05 million. Research analysts anticipate that Organovo will post -0.77 earnings per share for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.